Knee replacement is the common joint replacement surgery undertaken for patients with knee damaging diseases such as osteoarthritis, post-traumatic arthritis or rheumatoid arthritis. By product type, the global knee replacement market is segmented as follows: primary knee replacement (cemented or cementless), partial knee replacement and revision knee replacement. Implants are generally made of metal alloys, ceramic material, or plastic.
The global knee replacement market is presently consolidated into the largest manufacturers: Stryker Corporation, Zimmer Biomet, Smith & Nephew and DePuy / Johnson & Johnson.
As mentioned in our blog posts, Stryker, Smith & Nephew Square Off Over Total Knee Replacements and Stryker Marks Robotic Joint Replacement Milestone, innovative product designs and advancements in robotics, computer-navigated surgeries, smart implants, nanotechnology, 3D printing, biologics and tissue engineering will contribute to market growth. Hospitals are adopting robotic surgical devices to be used by trained physicians to improve their outcomes. Many universities worldwide have research programs in robotics and are awarding degrees on the subject, leading to roboticists increasingly being hired by top companies to link mobile robots into existing IT systems. The hip and knee surgical robot device market stood at $84 million in 2015, and is anticipated to reach $4.6 billion by 2022.
In Q3 2017, Stryker sold 33 Mako robots, compared with 30 robots in Q3 2016. In Q2 2017, Stryker installed 26 Mako robots. Of these 33 robots, 23 were installed in the United States. Around 40% of US sales are expected to be in competitive accounts. Stryker is training surgeons on its total knee application with Mako robots to increase its utilization rate. Around 600 surgeons were trained in Q3 2017.
Of the total installed Mako base in the United States, more than 50% is used to perform total knee procedures. Around 9,400 Mako total knee surgeries have been performed around the world since the launch. Between Q2 2017 and Q3 2017, Mako total knee procedures increased more than 50%. Stryker announced the commercial launch of Mako TKA in March 2017. The company held a limited launch of the product in June 2016.
In Q3 2017, Stryker received FDA 510(k) clearance for a cementless product offering that it aims to use with Mako TKA. Since the product is very popular among customers, it should boost Mako utilization rates. Stryker is continuously striving to invest in expanding access to its Mako robots and Mako’s indications of use. The company has initiated a number of trials and clinical studies to prove the efficiency of Mako procedures.